Silo Pharma Announces Device And CMC Development Master Plan With Resyca BV For Nose-To-Brain Drug Delivery; Promising Safety And Therapeutic Benefit Observed; Plan Supports IND-Enabling Studies For Lead Candidate SPC-15, An Intranasal Treatment For PTSD
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has announced a development master plan with Resyca BV for a nose-to-brain drug delivery device. The plan supports IND-enabling studies for SPC-15, an intranasal treatment for PTSD, with promising safety and therapeutic benefits observed.
July 18, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma's partnership with Resyca BV for a nose-to-brain drug delivery device and promising results for SPC-15 could positively impact the company's stock in the short term.
The partnership with Resyca BV and the promising safety and therapeutic benefits observed for SPC-15 are likely to boost investor confidence in Silo Pharma. This development supports IND-enabling studies, which is a critical step towards regulatory approval and commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100